Hypertension as a predictor of outcome and treatment response to cetuximab: A retrospective analysis of NCIC CTG CO.17.

Shelly Sud; Christopher J O'Callaghan; Caleb Jonker; Christos Stelios Karapetis; Timothy Jay Price; Niall C Tebbutt; Jeremy David Shapiro; Guy A Van Hazel; Nick Pavlakis; Peter Gibbs; Mark Jeffery; Lillian L Siu; Sharlene Gill; Ralph Wong; Derek J Jonker; Dongsheng Tu; Rachel Anne Goodwin

Conference Proceedings

Hypertension as a predictor of outcome and treatment response to cetuximab: A retrospective analysis of NCIC CTG CO.17.

Shelly Sud, Christopher J O'Callaghan, Caleb Jonker, Christos Stelios Karapetis, Timothy Jay Price, Niall C Tebbutt, Jeremy David Shapiro, Guy A Van Hazel, Nick Pavlakis, Peter Gibbs, Mark Jeffery, Lillian L Siu, Sharlene Gill, Ralph Wong, Derek J Jonker, Dongsheng Tu, Rachel Anne Goodwin

JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2016

DOI: 10.1200/jco.2016.34.4_suppl.256

Abstract

256 Background: Adrenergic receptor stimulation is involved in development of hypertension (HTN), and is implicated in progression and dissemination of metastases in tumour types such as colon cancer (CRC). Adrenergic antagonists, such as beta-blockers (BB), demonstrate inhibition of invasion and migration in CRC cell lines and have been associated with decreased mortality in advanced CRC. We examined the association of baseline HTN (BHTN) and use of BB on overall (OS) or progression-free survival (PFS) of pts with pre-treated, chemotherapy refractory, metastatic CRC (mCRC). We also examined BHTN and BB use as predictors of Cetuximab (CET) efficacy. Methods: Using data from NCIC CO.17 (CET ..

View full abstract